Stocks and Investing Stocks and Investing
Tue, August 23, 2011

XNPT, CYTK, SGRP, MNKD, THLD, LPSN Are Seasonally Ripe To Go Up In the Next Five Weeks


Published on 2011-08-23 10:01:05 - WOPRAI
  Print publication without navigation


August 23, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of XENOPORT INC (NASDAQ:XNPT), CYTOKINETICS INC (NASDAQ:CYTK), SPAR GROUP INC (NASDAQ:SGRP), MANNKIND CORP (NASDAQ:MNKD), THRESHOLD PHARMACEUTICALS (NASDAQ:THLD), LIVEPERSON INC (NASDAQ:LPSN) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Up:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     XNPT       XENOPORT INC                        16.84%              66.67% (4 of 6)         Friday, September 16th 2011
     CYTK       CYTOKINETICS INC                    13.80%              85.71% (6 of 7)         Friday, September 16th 2011
     SGRP       SPAR GROUP INC                      20.74%              88.89% (8 of 9)         Monday, September 5th 2011
     MNKD       MANNKIND CORP                       21.44%              100.00% (7 of 7)        Friday, September 30th 2011
     THLD       THRESHOLD PHARMACEUTICALS           15.55%              66.67% (4 of 6)         Friday, September 16th 2011
     LPSN       LIVEPERSON INC                      14.27%              90.91% (10 of 11)       Monday, September 19th 2011
XENOPORT INC (NASDAQ:XNPT) - XenoPort, Inc., a biopharmaceutical company, focuses on developing internally discovered product candidates that utilize the bodys natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. The company licenses its lead product candidate XP13512, a transported prodrug of gabapentin, to Astellas Pharma Inc. in Japan and five Asian countries, as well as to Glaxo Group Limited (GSK) in the United States and internationally. Astellas and GSK filed new drug applications for the approval of XP13512 as a treatment for restless legs syndrome in Japan and the United States. The company also develops Arbaclofen Placarbil, which is under Phase IIb clinical trials for the treatment of gastroesophageal reflux disease. In addition, it develops Arbaclofen Placarbil that has completed Phase II clinical trials for the treatment of spasticity. Further, the company develops XP21279, a transported prodrug of L-Dopa, which has completed Phase I clinical trials for the treatment of Parkinsons disease; and XP21510, a transported prodrug of tranexamic acid, that is in preclinical stages for the treatment of menorrhagia or heavy menstrual bleeding. XenoPort, Inc. has strategic alliances with Astellas Pharma, Inc. and Glaxo Group Limited. The company was founded in 1999 and is based in Santa Clara, California.

CYTOKINETICS INC (NASDAQ:CYTK) - Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. It primarily offers omecamtiv mecarbil, a cardiac muscle myosin activator, which is in Phase I/IIa clinical trials for the treatment of heart failure; CK-2017357, which is a Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis; and CK-2066260, a fast skeletal muscle sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting. The companys cancer treatment products under development stage comprise ispinesib, SB-743921, and GSK-923295. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. The company was founded in 1997 and is headquartered in South San Francisco, California.

SPAR GROUP INC (NASDAQ:SGRP) - SPAR Group, Inc., together with its subsidiaries, provides merchandising and other marketing services to manufacturers, distributors, and retailers in the United States and internationally. The company primarily offers syndicated services, such as regularly scheduled, routed merchandising, and marketing services provided at the retail store level; and dedicated services, including store set-ups, store remodels, and fixture installations. It also provides project services comprising in-store services, such as new store openings, new product launches, special seasonal or promotional merchandising, focused product support, product recalls, in-store product demonstrations, and in-store product sampling, as well as new store sets and existing store resets, re-merchandising, and remodels and category implementations under annual or stand-alone project contracts or agreements. In addition, the company offers in-home and in-office assembly services, and in-store event staffing services consisting of in-store product samplings and in-store product demonstrations. Further, SPAR Group provides various other marketing services comprising test market research, including testing promotion alternatives, new products and advertising campaigns, as well as packaging, pricing, and location changes at the store level; mystery shopping services, such as calling anonymously on retail outlets to check on distribution or display of a brand and to evaluate products, service of personnel, and conditions of store; data collection services consisting of gathering sales and other information for analysis and interpretation; and radio frequency identification services. The companys customers include manufacturers, mass merchandisers, electronics store chains, drug store chains, convenience and grocery stores, and other retail outlets, such as discount stores, and home and office supply centers. SPAR Group, Inc. was founded in 1967 and is headquartered in Tarrytown, New York.

MANNKIND CORP (NASDAQ:MNKD) - MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate, AFREZZA, a rapid-acting insulin that has completed Phase III clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company is also preparing to initiate a Phase II study of MKC1106-MT in patients with advanced melanoma. Its products also include MKC253 (GLP-1), a Phase I clinical trials product for the treatment of type 2 diabetes; and MKC1106-PP, a Phase I clinical trials product for the treatment of diverse tumor types, metastatic diseases, and/or progressive, refractory disease. In addition, the company conducts preclinical studies of drug candidates, MKC204, which may have the potential to treat certain malignancies and inflammatory diseases; MKC180, an obesity compound; and MKC1106-NS, a cancer immunotherapy product. MannKind Corporation was founded in 1991 and is based in Valencia, California.

THRESHOLD PHARMACEUTICALS (NASDAQ:THLD) - Threshold Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. Its product line includes TH-302, a product candidate in Phase I and Phase I/II for the potential treatment of patients with cancer; and 2DG, a product candidate for the potential treatment of patients with cancer and has been evaluated in a Phase I clinical trial alone and in combination with docetaxel as a combination therapy. The company was founded in 2001 and is headquartered in Redwood City, California.

LIVEPERSON INC (NASDAQ:LPSN) - LivePerson, Inc. provides online engagement solutions that facilitate real-time assistance and advice. It connects businesses and independent service providers with consumers seeking help on its hosted software platform. The companys hosted platform supports and manages real time online interactions, such as chat, voice/click-to-call, email, and self service/knowledgebase from a single agent desktop. The company offers LivePerson Enterprise for Sales solution that combines online site traffic monitoring software with a rules engine to enable its clients to proactively engage Web site visitors; and LivePerson Enterprise for Service solution, which enhances its contact center by identifying customers who are struggling with their self help experience, and connecting them to a live customer care specialist. It also offers LivePerson Premier that helps businesses in visitor engagement and provides insights into online sales initiatives and customer care issues; LivePerson Pro that enables chat agents to segment visitors based on various attributes, and target the candidates for a chat in real time; and Multichannel Contact Center Solutions, which help businesses to add LivePersons voice, email, and knowledgebase channels to LivePerson Pro or LivePerson Premier. In addition, the company provides professional services and value added business consulting services. LivePerson, Inc. sells its products and services through direct and indirect sales channels to financial, retail, telecommunications, technology, and travel/hospitality industries, as well as to small and mid-sized businesses, Internet businesses, online merchants, universities, libraries, government agencies, and not-for-profit organizations in the United States, Canada, Israel, and Europe. The company was founded in 1995 and is headquartered in New York, New York.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641